Research Topics
Species | Thomas WaldmannSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Survival adjustment of mature dendritic cells by IL-15Sigrid P Dubois
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 102:8662-7. 2005..These findings support the hypothesis that DCs mediate the effect of IL-15 on CD8+/CD44(hi) memory phenotype T cells...- Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemiaThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
Blood 121:476-84. 2013.... 
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Immunol 6:595-601. 2006..As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases...- IL-15 in the life and death of lymphocytes: immunotherapeutic implicationsThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD 20892-1374, USA
Trends Mol Med 9:517-21. 2003 - Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odysseyThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH Building 10, Bethesda, Maryland 20892 1374, USA
J Clin Immunol 27:1-18. 2007.... - Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphomaT A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1374, USA
Oncogene 26:3699-703. 2007..These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma... - ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emittersThomas Waldmann
National Institutes of Health, National Cancer Institute, Bldg 10, Room 4N115, 10 Center Drive 1374, Bethesda, MD 20892 1374, USA
Leuk Lymphoma 44:S107-13. 2003.... - Immunotherapy: past, present and futureThomas A Waldmann
Metabolism Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Nat Med 9:269-77. 2003 - The use of antibodies against the IL-2 receptor in transplantationT A Waldmann
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Curr Opin Immunol 10:507-12. 1998..In a randomized trial, when added to standard cyclosporin-based immunosuppression, daclizumab significantly reduced the frequency of acute rejection of renal transplants... - Effective cancer therapy through immunomodulationThomas A Waldmann
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
Annu Rev Med 57:65-81. 2006.... - The meandering 45-year odyssey of a clinical immunologistThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1374, Building 10, Room 4N115, Bethesda, Maryland 20892 1374, USA
Annu Rev Immunol 21:1-27. 2003..New forms of therapy directed at IL-2 and IL-15 receptors may be effective against certain neoplastic diseases and autoimmune disorders and in the prevention of allograft rejection... - The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogensT A Waldmann
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Annu Rev Immunol 17:19-49. 1999..New approaches directed toward IL-15, its receptor, or its signaling pathway may be of value in the therapy of these disorders... - The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseasesThomas Waldmann
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Arthritis Res 4:S161-7. 2002..New approaches directed toward inhibiting the actions of the inflammatory cytokine, IL-15, are proposed for an array of autoimmune disorders including rheumatoid arthritis as well as diseases associated with the retrovirus HTLV-I... - Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A Waldmann
Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
Blood 117:4787-95. 2011.... - A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's diseaseRonald R Buggage
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892 1857, USA
Ocul Immunol Inflamm 15:63-70. 2007..To investigate the safety and efficacy of daclizumab (Zenapax, humanized anti-Tac, HAT) in controlling the ocular manifestations of Behçet's disease... - Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemiaJohn C Morris
Metabolism Branch, Center for Cancer Research, and Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:401-6. 2006.... - Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of proteinVladimir S Talanov
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Nucl Med Biol 33:469-80. 2006..The in vivo studies also revealed that the N-methyl modification resulted in a superior statinated product... - Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosisBibiana Bielekova
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:5941-6. 2006..This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity... - Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurementsLaszlo Bene
Department of Biophysics and Cell Biology, Medical and Health Science Center, Research Center for Molecular Medicine, University of Debrecen, Hungary
Biochim Biophys Acta 1744:176-98. 2005.... - Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25Zhuo Zhang
Metabolism Branch, NCI, NIH, Bldg 10, Room 4N115, 10 Center Drive, Bethesda, MD 20892-1374, USA
Blood 108:1007-12. 2006..These results that demonstrate a significantly improved therapeutic efficacy by combining (211)At-7G7/B6 with daclizumab support a clinical trial of this regimen in patients with ATL... - Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsChristopher A Klebanoff
Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
Proc Natl Acad Sci U S A 102:9571-6. 2005..Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of T(CM) may be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination... - Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticleHisataka Kobayashi
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
Neoplasia 7:984-91. 2005.... - Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptorsMeili Zhang
Metabolism Branch, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 108:705-10. 2006..We demonstrated that the expression of FcRgamma on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab... - ITK and IL-15 support two distinct subsets of CD8+ T cellsSigrid Dubois
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:12075-80. 2006..Thus, whereas ITK-dependent CD44(lo)CD122(lo) CD8(+) T cells appear to represent conventional CD8(+) T cells, IL-15-dependent CD44(hi)CD122(hi) CD8(+) T cells may have functions in both adaptive and innate immunity... - The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cellsNoriko Sato
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:588-93. 2007.... - The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemiaMeili Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1374, USA
Cancer Res 66:8227-32. 2006..In summary, (211)At-7G7/B6 could serve as an effective therapeutic agent for patients with CD25-expressing leukemias... - IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like diseaseFumi Miyagawa
Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 181:1109-19. 2008.... 
Receptor-directed therapy of T-cell leukemias and lymphomasJohn C Morris
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1457, USA
J Immunotoxicol 5:235-48. 2008..The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed...- IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cellsMasaki Terabe
Vaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20893, USA
J Immunol 180:7276-86. 2008..1(+) T cell subset, CD8alphaalphaNK1.1(+) T cells, and that IL-15-transgenic mice may be a useful resource for studying the functional relevance of CD8(+)NK1.1(+) T cells... - IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosisSangKon Oh
Vaccine Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
Proc Natl Acad Sci U S A 105:5201-6. 2008..These findings suggest new vaccine strategies against infections and cancers, especially in individuals with CD4-deficiency... - Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cellsBärbel I de Bakker
Applied Optics Group, Faculty of Science and Technology, MESA Research Institute for Nanotechnology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands
J Cell Sci 121:627-33. 2008..Our results should aid understanding the action of the IL2R-IL15R system in T cell function and also might contribute to the more rationale design of IL2R- or IL15R-targeted immunotherapy agents for treating human leukemia... - Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor actionSigrid Dubois
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
J Immunol 180:2099-106. 2008..Thus, a preassociation with IL-15Ralpha-IgG1-Fc enhances the activities of IL-15 in vivo and in vitro that may be useful in the treatment of tumors... - Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodiesMatthew K Robinson
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 14:875-82. 2008..We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived alpha-emitting radioisotope (211)At... - Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in miceLiyanage P Perera
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Bethesda, MD 20892 1374, USA
J Virol 81:8774-83. 2007..Thus, Wyeth IL-15 and MVA IL-15 viruses hold promise as more-efficacious and safe alternatives to the Dryvax vaccine... - Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1Meili Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute, PET Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:8444-8. 2007..001). In summary, radiolabeled HeFi-1 is very promising for the treatment of CD30-expressing leukemias and lymphomas, and the combination regimen of (211)At-HeFi-1 with unmodified HeFi-1 enhanced the therapeutic efficacy... - A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancyJohn C Morris
Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
Clin Cancer Res 13:958-64. 2007..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points... - Preparation and in vivo evaluation of novel linkers for 211At labeling of proteinsVladimir S Talanov
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Nucl Med Biol 31:1061-71. 2004..Formation of 11, however, is found to require the absence of NCS. Elimination of acetic acid is found to have no effect on radiolabeling efficiency or yield for either of these reactions... - Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiationHisataka Kobayashi
Metabolism Branch, Radiation Biology Branch, and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1002, USA
Clin Cancer Res 10:7712-20. 2004..Such information might be applied to optimize the efficacy of subsequent or concurrent therapies including radiolabeled antibodies or other anticancer agents in combination with external beam therapies... - Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationRobert B Nussenblatt
The National Eye Institute, Laboratory of Immunology, NIH, Building 10, 10 Center Drive, Bethesda, MD, USA
J Autoimmun 21:283-93. 2003..These studies suggest that anti-IL-2 receptor blockade could be useful in the treatment of Th1-mediated autoimmune conditions... - Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1HZhuo Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute/NIH, Building 10, Room 4N115, 10 Center Drive, Bethesda, MD 20892-1374, USA
Cancer Res 63:6453-7. 2003..This study provides support for a clinical trial of Campath-1H in the treatment of patients with T-cell leukemias and lymphomas... - Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiographyHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
Magn Reson Med 50:758-66. 2003..In conclusion, DAB-G5 and PAMAM-G4 can be used to identify lymph nodes and lymphatic vessels, respectively. Their rapid excretion makes these compounds potentially attractive for human use... - Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chaseHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Bioconjug Chem 14:1044-7. 2003..Moreover, it permits the repeated injection of the contrast agent and the "avidin switch" during a single MR experiment... - Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507Zhuo Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute/NIH, Bldg 10, Rm 4N115, 10 Center Drive, Bethesda, MD 20892-1374, USA
Blood 102:284-8. 2003..These results demonstrate that MEDI-507 has therapeutic efficacy on ATL in vivo and provides support for a clinical trial involving this monoclonal antibody in the treatment of patients with CD2-expressing leukemias and lymphomas... - Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunitySangKon Oh
Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 100:3392-7. 2003.... - Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenograftsMeili Zhang
Metabolism and Radiation Oncology Branches, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1374, USA
Proc Natl Acad Sci U S A 100:1891-5. 2003..Thus, Pretarget radioimmunotherapy is very promising and could represent the next generation in the treatment of lymphoma and leukemia... - Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agentHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer, NIH, Bethesda, Maryland 20892, USA
Cancer Res 63:271-6. 2003.... - Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotinZhengsheng Yao
Nuclear Medicine Department of the Warren G. Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Cancer Res 62:5755-60. 2002.... - Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugatesRaya Mandler
Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland 20982-1002, USA
Bioconjug Chem 13:786-91. 2002..However, unlike H:ABA-GA, the immunoconjugate H:APA-GA caused stable tumor regression (in 25% of the recipients), showing a qualitative improvement with potential clinical relevance... - Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213Meili Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 100:208-16. 2002..The findings of this study support the use of this combination approach in a clinical trial in patients with IL-2R alpha-expressing leukemias... - Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemiaChalet Tan
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1374, USA
Cancer Res 62:1083-6. 2002.... - GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell linesJanos Matko
Department of Biophysics and Cell Biology, Cell Biophysics Research Group of the Hungarian Academy of Sciences, University of Debrecen, Health Science Center, Debrecen, Hungary
Eur J Biochem 269:1199-208. 2002..g. CD48). Based on these data, the integrity of these GPI-microdomains seems critical in signal transduction through the IL-2R complex... - Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cellsSigrid Dubois
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 100:14169-74. 2003..Thus, IL-15 induces T cell proliferation mainly via FKBP12-mediated p70S6K activation. In contrast, IL-2 signaling involves multiple pathways that include at least one additional pathway that depends on FKBP12.6... - Interleukin-2 receptor-directed therapies for cutaneous lymphomasFrancine M Foss
Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
Hematol Oncol Clin North Am 17:1449-58. 2003.... - IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cellsSangKon Oh
Vaccine Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 101:15154-9. 2004..Conversely, high-avidity CTLs are diminished in IL-15Ralpha knockout mice. These results provide an explanation of CD8+ T cell avidity maturation and may contribute to the design of novel vaccines... - Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibodyMeili Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 4N115, 10 Center Dr, Bethesda, MD 20892, USA
Blood 105:1231-6. 2005..01). The significantly improved therapeutic efficacy by combining flavopiridol with HAT provides support for a clinical trial in the treatment of ATL... - Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillanceHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 105:721-7. 2005..Furthermore, our observation provides the scientific basis for a novel strategy to prevent cancer development/metastasis... - Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemiaMeili Zhang
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1374, USA
Cancer Res 64:5825-9. 2004..Although NK cells may play a role in humans, in this murine model FcRgamma receptors on non-NK cells, such as polymorphonuclear leukocytes or monocytes, are required for the tumor-killing action of the antibodies directed toward CD25... - IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cellsGyörgy Vámosi
Cell Biophysics Research Group of the Hungarian Academy of Sciences, Debrecen, Hungary
Proc Natl Acad Sci U S A 101:11082-7. 2004..In addition, both alpha-chains were at least partially homodimerized/oligomerized, which could be the basis of distinct signaling pathways by the two cytokines... - Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseasesThomas A Waldmann
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Arthritis Res Ther 6:174-7. 2004.... - Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphomaJohn E Janik
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 104:3355-7. 2004..Serum sIL-2R levels were elevated in both patients with recurrent disease... - Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotinZhengsheng Yao
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3137-46. 2004..CONCLUSIONS: (213)Bi-DOTA-biotin, directed by the Pretarget method to tumor-targeted B3-SA, showed a therapeutic effect, although the therapeutic index was low. The source of the toxicity was most likely related to the renal toxicity... - Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agentHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1374, USA
J Natl Cancer Inst 96:703-8. 2004..Improving current magnetic resonance (MR) imaging methods using a newly synthesized nano-size paramagnetic molecule, G6, as a contrast agent, provides an attractive means toward attaining this goal... - Micro-MRI methods to detect renal cysts in miceHisataka Kobayashi
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Kidney Int 65:1511-6. 2004.... - Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)AtJon N Wesley
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Nucl Med Biol 31:357-64. 2004..7+/-2.4 days survival (p<0.001 versus controls) with (211)At labeled HAT. Thus, (211)At labeled HAT may have application in organ transplantation and in treatment of IL-2 receptor expressing T-cell leukemia... - Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activityRaya Mandler
Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, USA
Cancer Res 64:1460-7. 2004..In addition, the chemical linkage and the considerations in therapeutic regimen described here could be applied to other immunoconjugates for targeted therapy of a broad spectrum of cancers... - IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cellsChristopher A Klebanoff
Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
Proc Natl Acad Sci U S A 101:1969-74. 2004..These results provide several avenues for improving adoptive immunotherapy of cancer in patients... - Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modificationsMeyoung-Kon Kim
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, Bethesda, Maryland 20892, USA
Nucl Med Biol 29:139-46. 2002..3% ID/g for 99mTc-MAG3-Fab, whereas the glycolation resulted in a drastic reduction of the renal uptake at 15 min. We demonstrated that the renal clearance and the tumor targeting of Fab could be optimized by chemical modifications...